Bristol-Myers Squibb Company

Bristol-Myers Squibb Company develops and sells biopharmaceutical products worldwide. Products treat diseases such as hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience conditions. Notable products include Eliquis, Opdivo, Pomalyst/Imnovid, Orencia, Sprycel, Yervoy, Empliciti, Abecma, Reblozyl, and more. The company offers various treatments for cancer, multiple myeloma, rheumatoid arthritis, psoriatic arthritis, melanoma, and more. Products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Overview

Sector

Pharmaceutical

Target Price

0.0 USD

Current Price

46.9 USD

Potential

-100%

Strengths

The company has high returns. ROIC (23.02%) is higher than the sector mean (16.32%).
EV/EBITDA (8.58) is lower than the sector mean (21.51).
Price to free cash flow (7.06) is lower than the sector mean.
Strong EBITDA Margin of 33.98%.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (2.45) is higher than the sector mean.
EV/EBIT (100.00) is significantly higher than the sector mean.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	8.4
Price/Free Cash Flow'	6.8
ROIC	23.0%
Net Debt/EBITDA	2.4